Unknown

Dataset Information

0

Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies.

ABSTRACT: A library of novel naproxen based 1,3,4-oxadiazole derivatives (8-16 and 19-26) has been synthesized and screened for cytotoxicity as EGFR inhibitors. Among the synthesized hybrids, compound2-(4-((5-((S)-1-(2-methoxynaphthalen-6-yl)ethyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol(15) was the most potent compound against MCF-7 and HepG2cancer cells with IC50 of 2.13 and 1.63 µg/mL, respectively, and was equipotent to doxorubicin (IC50 1.62 µg/mL) towards HepG2. Furthermore, compound 15 inhibited EGFR kinase with IC50 0.41 μM compared to standard drug Erlotinib (IC50 0.30 μM). The active compound induces a high percentage of necrosis towards MCF-7, HePG2 and HCT 116 cells. The docking studies, DFT and MEP also supported the biological data. These results demonstrated that these synthesized naproxen hybrids have EGFR inhibition effects and can be used as leads for cancer therapy.

SUBMITTER: Alam MM 

PROVIDER: S-EPMC8469912 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies.

Alam Mohammad Mahboob MM   Nazreen Syed S   Almalki Abdulraheem S A ASA   Elhenawy Ahmed A AA   Alsenani Nawaf I NI   Elbehairi Serag Eldin I SEI   Malebari Azizah M AM   Alfaifi Mohammad Y MY   Alsharif Meshari A MA   Alfaifi Sulaiman Y M SYM  

Pharmaceuticals (Basel, Switzerland) 20210828 9

A library of novel naproxen based 1,3,4-oxadiazole derivatives (<b>8</b>-<b>16</b> and <b>19</b>-<b>26</b>) has been synthesized and screened for cytotoxicity as EGFR inhibitors. Among the synthesized hybrids, compound2-(4-((5-((<i>S</i>)-1-(2-methoxynaphthalen-6-yl)ethyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)phenol(<b>15</b>) was the most potent compound against MCF-7 and HepG2cancer cells with IC<sub>50</sub> of 2.13 and 1.63 µg/mL, respectively, and was equipotent to  ...[more]

Similar Datasets

Unknown 1,3,4-oxadiazole derivatives: synthesis, characterization, antimicrobial potential, and computational studies.
| S-EPMC4131560 | biostudies-literature
Unknown Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives.
| S-EPMC10189396 | biostudies-literature
Unknown Molecular Docking, Computational, and Antithrombotic Studies of Novel 1,3,4-Oxadiazole Derivatives.
| S-EPMC6274789 | biostudies-literature
Unknown Synthesis and Anticancer Evaluation of New 1,3,4-Oxadiazole Derivatives.
| S-EPMC8148175 | biostudies-literature
Unknown Synthesis, molecular docking study and anticancer activity of novel 1,3,4-oxadiazole derivatives as potential tubulin inhibitors.
| S-EPMC9947267 | biostudies-literature
Unknown Synthesis, Biological Evaluation and Computational Studies of New Hydrazide Derivatives Containing 1,3,4-Oxadiazole as Antitubercular Agents.
| S-EPMC9735621 | biostudies-literature
Unknown Synthesis of Some New 1,3,4-Oxadiazole Derivatives and Evaluation of Their Anticancer Activity.
| S-EPMC10753699 | biostudies-literature
Unknown Synthesis, anticancer evaluation and molecular docking studies of new benzimidazole- 1,3,4-oxadiazole derivatives as human topoisomerase types I poison.
| S-EPMC7470102 | biostudies-literature
Unknown Design, Synthesis and Bioactivity Evaluation of Novel β-carboline 1,3,4-oxadiazole Derivatives.
| S-EPMC6150204 | biostudies-literature
Unknown Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors.
| S-EPMC10560058 | biostudies-literature